BioFocus DPI and Oncodesign forge alliance to provide integrated oncology drug discovery services
BioFocus DPI and Oncodesign announced that they have joined forces to offer a comprehensive oncology drug discovery service. The alliance combines BioFocus DPI’s target discovery and screening capabilities with Oncodesign’s experimental pharmacological and biomarker expertise in oncology. In addition, the partners will contribute their complementary medicinal chemistry expertise to form a drug discovery service specialized in the rapid generation of promising anticancer drug candidates.
“Oncodesign’s extensive experience in developing anticancer therapeutics complements BioFocus DPI’s medicinal chemistry and biology expertise, creating a focused oncology drug discovery offering that can move rapidly from hit finding to pre-clinical candidate,” said Chris Newton, Senior Vice President, BioFocus DPI. “As the industry’s understanding of disease pathways has grown considerably in recent years, the need for specialized drug discovery services has also grown. We expect that our current and future customers will benefit greatly from the synergies that this alliance offers.”
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.